Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, Chief Financial Officer | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 41,554 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 41,554 · Balance 41,554 F1: This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $77.01 · Expires 2036-07-01 | Direct | 127,432 |
Reported balance
After 2026-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-01 · Grant · Acquired 127,432 · Balance 127,432 F2: This option vests one-fourth on such date and then 1/48th monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter.
F2: This option vests one-fourth on such date and then 1/48th monthly thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 20:44 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 127,432 | $0.00 Strike: $77.01 | $0.00 |
DisclosureSEC source: 0001159036-26-000095 · wk-form4_1783025038.xml · derivative · entry 2 Snellgrove Darren · CIK 0002137401 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,432 Underlying: Common Stock · 127,432 shares Expires 2036-07-01 F2 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:44 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 41,554 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000095 · wk-form4_1783025038.xml · derivative · entry 1 Snellgrove Darren · CIK 0002137401 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,554 Underlying: Common Stock · 41,554 shares Expires not disclosed F1 · derivative.exercise_date: This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter. F1 · derivative.expiration_date: This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.